Antibacterial Effect of Silver Nanoparticles on Multi Drug Resistant Pseudomonas Aeruginosa

Multidrug resistant organisms have been taunting the medical world for the last few decades. Even with new antibiotics developed, resistant strains have emerged soon after. With the advancement of nanotechnology, we investigated colloidal silver nanoparticles for its antimicrobial activity against Pseudomonas aeruginosa. This organism is a multidrug resistant which contributes to the high morbidity and mortality in immunocompromised patients. Five multidrug resistant strains were used in this study. The antimicrobial effect was studied using the disc diffusion and broth dilution techniques. An inhibition zone of 11 mm was observed with 10 μg dose of the nanoparticles. The nanoparticles exhibited MIC of 50 μg/ml when added at the lag phase and the subinhibitory concentration was measured as 100 μg/ml. The MIC50 value showed to be 15 μg/ml. This study suggests that silver nanoparticles can be further developed as an antimicrobial agent, hence decreasing the burden of the multidrug resistance phenomena.

Authors:

• Athirah Nur Amirulhusni
• Navindra Kumari Palanisamy
• Zaini Mohd-Zain
• Liew Jian Ping
• R.Durairaj

Keywords:

• Antimirobial activity
• Multidrug resistance
• Pseudomonas aeruginosa
• Silver nanoparticles

References:

[1] Goossens, H. (2003). "Susceptibility of multi-drug-resistant
Pseudomonas aeruginosa in intensive care units: results from the
European MYSTIC study groupÔÇá." Clinical Microbiology and Infection
9(9): 980-983.
[2] Kerr, K. G. and A. M. Snelling (2009). "Pseudomonas aeruginosa: a
formidable and ever-present adversary." Journal of Hospital Infection
73(4): 338-344.
[3] Foran, S. M. (2009). Therapeutic Properties of Silver : An Historical
and Technical Review. Quanta.
[4] Mudshinge, S. R., A. B. Deore, et al. (2011). "Nanoparticles: Emerging
carriers for drug delivery." Saudi Pharmaceutical Journal 19(3): 129-
141.
[5] Kim, J. S., E. Kuk, et al. (2007). "Antimicrobial effects of silver
nanoparticles." Nanomedicine: Nanotechnology, Biology and Medicine
3(1): 95-101.
[6] Bhupendra Chudasama, A. K. V., Nidhi Andhariya, R. V. Metha, R. V.
Upadhyay (2010). "Highly bacterial resistant silver nanoparticles :
synthesis and antibacterial activities."
[7] Shahverdi, A. R., A. Fakhimi, et al. (2007). "Synthesis and effect of
silver nanoparticles on the antibacterial activity of different antibiotics
against Staphylococcus aureus and Escherichia coli." Nanomedicine:
Nanotechnology, Biology and Medicine 3(2): 168-171.
[8] Clinical and Laboratory Standards Institute (2000): Performance
standards for antimicrobial susceptibility testing (Wayne, P.A) 1995:
15th informational supplement. Document M100- S15.
[9] Ivan Sondi, B. S.-S. (2004). "Silver nanoparticles as antimicrobial agent
: a case study on E. coli as a model for Gram-negative bacteria." Journal
of Colloid and Interface Science: 177 - 182.
[10] Lisa A. Spacek, M. D., Ph.D.; Khalil G. Ghanem, M.D. (2011).
Pseudomonas aeruginosa, Unbound Medicine.
[11] Yamanaka, M., K. Hara, et al. (2005). "Bactericidal actions of a silver
ion solution on Escherichia coli, studied by energy-filtering
transmission electron microscopy and proteomic analysis." Applied and
environmental microbiology 71(11): 7589.
[12] Batarseh, K. I. (2004). "Anomaly and correlation of killing in the
therapeutic properties of silver (I) chelation with glutamic and tartaric
acids." Journal of Antimicrobial Chemotherapy 54(2): 546-548.